

Anti-Human CD274/PD-L1-148Nd

Catalog: 3148017B

Package Size: 100 tests

Storage: Store product at 4°C. Do not freeze.

Reactivity: Chimpanzee, Squirrel Monkey, African Green, Marmoset,

Clone: 29E.2A3


Isotype: IgG2b

Formulation: Antibody stabilizer with 0.05% Sodium Azide

Technical Information

Validation: Each lot of conjugated antibody is quality control tested by CyTOF[®] analysis of stained cells using the appropriate positive and negative cell staining and/or activation controls.

Recommended Usage: The suggested use is 1 µl for up to 3 × 10⁶ live cells in 100 µl. It is recommended that the antibody be titrated for optimal performance for each of the desired applications.



Human PBMCs were incubated for 3 days in media alone (left) or with PHA (right) and then cells were stained with 170Er-anti-CD3 (UCHT1) and 148Nd-anti- CD274/PD-L1 (29E.2A3). Lymphocytes are displayed in the analysis.

Description

PD-L1 (also known as CD274, B7-H1), one of the ligands for programmed cell death 1 (PD-1), is an immune-inhibitory receptor belonging to the CD28/cytotoxic T lymphocyte antigen 4 (CTLA-4) family. It can deliver an inhibitory signal to PD-1/B7-1 expressing T cells, resulting in immune suppressive effects. PD-L1 is expressed on activated T cells, B cells, NK cells, DCs, macrophages, and bone marrow-derived mast cells. PD-L1 expression is also found on a wide range of human tumors. In addition, studies have show that PD-L1 expression strongly correlates with unfavorable prognosis in kidney, ovarian, bladder, breast, liver, gastric, and pancreatic cancer, but not in non-small cell lung cancer (NSCLC). Most importantly, these studies reveal that higher expression of PD-L1 may facilitate advancement of tumor stage and increase the invasion potential. PD-L1 expression can be induced by many inflammatory mediators and cytokines, of which Interferon-γ (IFN-γ) is the most potent.

References

Bandura, D. R., et al. Mass Cytometry: Technique for Real Time Single Cell Multitarget Immunoassay Based on Inductively Coupled Plasma Time-of-Flight Mass Spectrometry. *Analytical Chemistry* 81:6813-6822, 2009.

Ornatsky, O. I., et al. **Highly Multiparametric Analysis by Mass Cytometry.** *J Immunol Methods* 361 (1-2):1-20, 2010.

For technical support visit fluidigm.com/support

North America +1 650 266 6100 | Toll-free: +1 866 358 4354 in the US | support.northamerica@fluidigm.com **Europe** +33 1 60 92 42 40 | support.europe@fluidigm.com

China (excluding Hong Kong) +86 21 3255 8368 | techsupportchina@fluidigm.com **Japan** +81 3 3662 2150 | techsupportjapan@fluidigm.com

All other Asian countries +1 650 266 6100 | techsupportasia@fluidigm.com **Central and South America** +1 650 266 6100 | techsupportlatam@fluidigm.com

For Research Use Only. Not for use in diagnostic procedures.

This product contains antibodies manufactured by and sold under license from BioLegend and licensees thereof.

Information in this publication is subject to change without notice. **Safety data sheet information** fluidigm.com/sds **Patent and license information** fluidigm.com/legalnotices | Fluidigm, the Fluidigm logo, and CyTOF are trademarks or registered trademarks of Fluidigm Corporation in the United States and/or other countries. © 2015 Fluidigm Corporation. All rights reserved. 07/2015